Multicenter Open Label Phase 2 Study of Isatuximab Plus Pomalidomide and Dexamethasone With Carfilzomib in Relapsed or Refractory Multiple Myeloma
Latest Information Update: 02 Sep 2024
At a glance
- Drugs Carfilzomib (Primary) ; Dexamethasone (Primary) ; Isatuximab (Primary) ; Pomalidomide (Primary)
- Indications Multiple myeloma
- Focus Therapeutic Use
- 09 Jan 2023 Status changed from recruiting to active, no longer recruiting.
- 13 Dec 2022 Study is expected to complete recruitment in 2022 and read primary end point in 2023, as per trial design presented at the 64th American Society of Hematology Annual Meeting and Exposition.
- 13 Dec 2022 Trial design presented at the 64th American Society of Hematology Annual Meeting and Exposition.